Navigation Links
XTENT Announces Third Quarter 2008 Financial Results
Date:11/4/2008

d approximately $210,000 in expenses in connection with this workforce reduction including approximately $7,000 of non-cash expenses. All of these expenses were incurred during the third quarter of 2008. Average cost savings from the workforce reduction initiative, combined with other cost saving initiatives planned by the company, is anticipated to be approximately $1.3 million each month.

"We remain encouraged by the level of enthusiasm expressed for our Custom NX customizable drug eluting stent systems at this year's TCT," commented Gregory D. Casciaro, XTENT's President and Chief Executive Officer. "Discussions with physicians at TCT were very positive and reinforce our belief that practitioners are interested in customizable stent technology."

"We have realized our anticipated cost reductions during the third quarter of 2008 and expect this favorable spending profile to continue through the fourth quarter," said Casciaro. "The total loss from operations has decreased by $4.3 million in the quarter ended September 30, 2008 as compared to the quarter ended June 30, 2008."

About XTENT

XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device. Note: XTENT(R) Custom NX(R) DES Systems have not been approved for sale by any regulatory authority.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding XTENT's business that are not h
'/>"/>

SOURCE XTENT, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. XTENT Announces Second Quarter 2008 Financial Results and Business Progress
2. XTENT Appoints Christopher M. Smith and Arthur T. Taylor to Board of Directors
3. XTENT Announces CUSTOM I Data Receives Recognition from EuroIntervention
4. XTENT to Present at Cowen and Companys 28th Annual Health Care Conference
5. XTENT Announces 2007 Financial Results
6. New study shows extent of harmful human influences on global ecosystems
7. XTENT Announces 2007 Financial Results Conference Call
8. XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe
9. XTENT Announces Third Quarter 2007 Financial Results
10. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2008 and to Provide a Business Update
11. Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 19, 2013 The deadline to ... this Friday, June 21 at midnight ET. This ... and innovative people who’ve raised the bar on ... http://www.minonline.com/ima . , Any consumer and b2b ... is eligible to enter. Additionally, advertising agencies and ...
(Date:6/19/2013)... Chrysler made news recently when it refused to accept the ... Jeep models in question are the 1993-2004 Jeep Grand Cherokee ... are vulnerable to fire and explosion in a crash. (1) ... have been alleged to catch fire or explode upon impact. ... rear-end crashes, which resulted in 44 deaths and the Liberty ...
(Date:6/19/2013)... New York (PRWEB) June 19, 2013 ... and pancreatic cancer continue to mount in courts throughout ... Food & Drug Administration (FDA) recently held a meeting ... drugs known as incretin mimetics. According to a ... additional data from the makers of Januvia and similar ...
(Date:6/19/2013)... - In a major international study led by researchers ... the targeted therapy ibrutinib continues to show remarkable promise ... lymphoma (MCL). , The most recent interim findings of ... the New England Journal of Medicine . Previous ... 54th American Society of Hematology Annual Meeting and Exposition. ...
(Date:6/19/2013)... A new understanding of the genetic process that can ... potentially dangerous lesions for some women, and also raises ... in certain cases suggesting they could actually trigger ... analysis provides a clearer picture of the chromosomal and ... sometimes leads to chronic infection and, in less than ...
Breaking Medicine News(10 mins):Health News:Entry Deadline for min’s Integrated Marketing Awards Is This Friday, June 21 2Health News:Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent 2Health News:Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent 3Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 2Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 3Health News:Ibrutinib continues strong showing against mantle cell lymphoma 2Health News:Genetics of cervical cancer raise concern about antiviral therapy in some cases 2
... out-of-pocket health care costs, CAMP HILL, Pa., Sept. ... to help consumers compare health plan options and,choose one ... is available,to consumers on Highmark member Web sites. ... said Kim,Bellard, Vice President of eMarketing and Customer Relationship ...
... President, SEIU-UHW and SEIU California State ... ... My name is Sal Rosselli,and I,m the President of SEIU United ... workers in healthcare, the,public sector, property services, and other industries throughout ...
... choices , MONDAY, Sept. 10 (HealthDay News) -- U.S. and ... a comprehensive recommendation on how much of what types of ... diets. , Both the American Dietetic Association and the Dietitians ... that 20 percent to 30 percent of energy needs should ...
... -- In lifesaving procedures to open blocked heart arteries ... use of the more expensive drug, abciximab, justified over ... Mayo Clinic study to be published in the current ... and now available as an e-publication, offers clinicians the ...
... Hundreds of Institutional Investors to Attend Conference, ... Board: SKVI / Website: http://www.skinvisible.com ), the ... topically,applied dermatology products, today announced that Mr. Terry ... annual Merriman Curhan Ford & Co.,Investor Summit on ...
... Through November 2007 -, GLENDALE, Calif., ... for applications for the 2008-2009 PowerBar Team ... athletes, coaches,nutritionists, trainers and health and fitness ... invited to visit, http://www.powerbar.com/teamelite/application to submit ...
Cached Medicine News:Health News:Highmark Blue Shield Introduces New Health Plan Comparison Tool for Consumers 2Health News:SEIU Endorses AB 8, 'An Opportunity to Make History' 2Health News:Experts Sort Out Good Fats From Bad 2Health News:Skinvisible to Present at Merriman Curhan Ford & Co.'s Investor Summit 2007 2Health News:PowerBar Issues Open Call for 2008-2009 PowerBar Team Elite(TM) Athlete Sponsorship Program 2
(Date:6/19/2013)... -- Ellen MacArthur Foundation meddelade i ... kommer att vara en partner för att hjälpa ... Efter stiftelsens framgångsrika partnerskap med Renault, BT/Cisco ... att ansluta sig som partner för att få ... verksamhet och stödja stiftelsens arbete inom utbildning. ...
(Date:6/19/2013)... , June 19, 2013 The Physician-Patient Alliance ... alarm fatigue. The need to urgently address this ... its Sentinel Event Alert #50 , "Medical device alarm safety ... database, between January 2008 and June 2012, there were 98 ... resulted in death (82%) , 13 resulted in permanent ...
(Date:6/19/2013)...   BioCision , a leader in advanced ... many areas of medical and scientific research, announced ... U.S. Patent Office that apply to two of ... handling to ensure the consistency of test conditions ... Patent number 8,388,912 covers CoolSink® ...
Breaking Medicine Technology:Ellen MacArthur Foundation presenterar Philips som global partner vid det konstituerande internationella toppmötet om cirkulär ekonomi 2Ellen MacArthur Foundation presenterar Philips som global partner vid det konstituerande internationella toppmötet om cirkulär ekonomi 3Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 2Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 3BioCision Announces Two New U.S. Patents for Thermo-Conductive Products that Standardize Sample Handling in Laboratory Research 2
... Inc. (Nasdaq: KERX ) today announced that ... from previous clinical trials of Zerenex™ (ferric citrate) were ... the American Society of Nephrology (ASN) Kidney Week 2011 ... ferric iron-based drug candidate, is currently in Phase 3 ...
... and WASHINGTON, Nov. 14, 2011 Nektar Therapeutics (NASDAQ: ... data for NKTR-192, a novel mu-opioid agonist, was presented ... Neuroscience being held November 12-16, 2011 in Washington, DC. ... for the treatment of acute pain.  It is designed ...
Cached Medicine Technology:Keryx Biopharmaceuticals Announces Highlights from Zerenex™ (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting 2Keryx Biopharmaceuticals Announces Highlights from Zerenex™ (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting 3Keryx Biopharmaceuticals Announces Highlights from Zerenex™ (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting 4Positive Data for Nektar's New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011 2Positive Data for Nektar's New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011 3Positive Data for Nektar's New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011 4Positive Data for Nektar's New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011 5Positive Data for Nektar's New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011 6
The BD LSR II can be configured with up to four fixed alignment lasers and the ability to detect up to 15 colors, utilizing a revolutionary optical design. The BD LSR II can be configured with a 488 ...
... mobile/portable flow cytometer especially suited for ... counting. The CyFlow allows to analyze ... to 2 fluorescence channels. Data acquisition, ... with a built-in PC employing Partec ...
Dual laser powered flow cytometer...
... IMMULITE 2000, a continuous random access ... 200 tests per hour, has been ... consolidation in medium- and high-volume laboratories. ... its self-explanatory graphical user interface, offers ...
Medicine Products: